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The association between cannabis use and psychosis 
is well established, with estimated odds ratios (ORs) 
of 1·4 for lifetime exposure and 2·1 for frequent use 
according to longitudinal population-based cohorts.1 
These results seem to show a dose-response eﬀ ect,1 
but have not taken account of a key component 
of cannabis—its potency. In The Lancet Psychiatry, 
Marta Di Forti and colleagues2 address this gap with 
a case-control analysis of ﬁ rst-episode psychosis. 
Strengths of the study include the large sample of 
patients (n=410), an impressive response rate for 
participation (461 [76%] of 606 individuals) and 
appropriate control for confounding by gender, 
ethnicity, education, employment status, and other 
drug use. 
Consistent with previous reports,1 patients with ﬁ rst-
episode psychosis were more likely than controls to 
have used cannabis on a daily basis. More importantly, 
however, this eﬀ ect was strongly dependent on the 
type of cannabis used. The investigators identiﬁ ed no 
associations between low-potency (hash) cannabis 
and psychosis, even with daily use. By contrast, the 
risk increased substantially for high-potency (skunk) 
cannabis, with ORs of 1·9 (95% CI 1·08–2·62) for 
use less than once per week, 2·7 (1·4–9·1) for use at 
weekends, and 5·4 (2·8–11·3) for use every day. 
These ﬁ ndings make a notable contribution to the 
existing literature on cannabis and psychosis. Previous 
studies1 reporting a stronger association in frequent 
users, have been unable to separate heaviness of use 
from some of its correlates. For example, as frequency 
of cannabis use rises, so does the regularity with 
which an individual carries out a stigmatised and 
widely illegal activity, which has important social and 
developmental implications. Simultaneously, time 
spent on other recreational activities, education, or 
work will typically decrease. Furthermore, cannabis 
is almost always smoked with tobacco in many 
countries, including the UK. This fact makes separation 
of the eﬀ ects of tobacco co-administration from 
those of cannabis itself challenging.3 These factors 
cannot explain the diﬀ erential associations between 
cannabis type and psychosis reported by Di Forti and 
colleagues,2 if skunk and hash are assumed to be used 
by similar populations in a similar manner.
Replication of these ﬁ ndings in longitudinal 
cohorts will be important. Ideally these studies 
should biologically quantify cannabinoid exposure 
in addition to self-reported use. These measures 
could account for individual patterns of use, such as 
titrating (using less cannabis) as potency increases.4 
Skunk is not only characterised by high concentrations 
of Δ-9-tetrahydrocannabinol (THC; about 15%), but 
also by scarcity of cannabidiol (<0·1%). By contrast, 
hash usually contains roughly 5% THC and about 4% 
cannabidiol.5 Examination of cumulative exposure 
to these cannabinoids could determine whether the 
results reported by Di Forti and colleagues might 
be explained by propsychotic eﬀ ects of THC,6 anti-
psychotic eﬀ ects of cannabidiol,7 or interactions 
between the two.8,9 Identiﬁ cation of the contribution 
of diﬀ erent cannabinoids might have implications for 
other mental health problems linked to cannabis, such 
as addiction.10
Di Forti and colleagues correctly state that causality 
cannot be established on the basis of their study, and 
this consideration is important. If causality exists, they 
calculate that 24% of ﬁ rst-episode cases in their South 
London catchment area might be attributable to high 
potency cannabis. This ﬁ gure is higher than their estimate 
for daily use in general (19%). If this interpretation 
is correct, cannabis potency is more important than 
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WHO recently estimated that 804 000 people world-
wide died by suicide during 2012.1 Suicide prevention 
experts have historically focused their attention on 
elevated risk during times of economic downturn. For 
instance, Stack and Haas estimated that more than 
900 suicides in the USA were attributable to the sharp 
rise in redundancies that occurred in 1981–82 during 
the early years of the Reagan administration, and which 
pushed the national unemployment rate up to its 
highest level since the interwar Great Depression era.2 
More recently, adverse eﬀ ects linked with the 2008 
economic crisis have also been reported. For example, 
Barr and colleagues reported that geographical regions 
in England with the greatest increases in levels of 
unemployment have also seen the largest rises in suicide 
risk, especially so for men. 3 
In The Lancet Psychiatry, Carlos Nordt and colleagues4 
report on their longitudinal analyses of suicide risk 
across 63 countries during years 2000–11. This 
paper builds on previous work examining data from 
54 countries that was published from the same WHO 
mortality dataset.5 What is novel about the current 
paper is its longitudinal modelling of the international 
eﬀ ect of unemployment at population level across a 
period that encompasses economic stability as well as 
the crisis and its aftermath. This approach has enabled 
the authors to estimate the number of excess suicides 
attributable to unemployment per se, as well as the 
number speciﬁ cally attributable to the recession and 
its wake. The nine-fold diﬀ erence between these 
two values is striking. It implies that national and 
international suicide prevention strategies need to 
target the ill eﬀ ects associated with unemployment in 
times of economic stability as well as during recession. 
The paper also highlights the fact that not all job losses 
necessarily have an equivalent eﬀ ect, because the eﬀ ect 
on suicide risk could be greatest in settings where being 
without work is fairly unusual.
Nordt and colleagues have correctly highlighted 
missing information from large and populous countries 
such as China and India, as well as most of the African 
continent, as the key limitation of the WHO mortality 
dataset that they examined.4 Another major restriction, 
one the authors did not address, is that examining 
ﬂ uctuating unemployment levels encompasses merely 
a fraction of complete societal exposure to the eﬀ ects 
of economic recession and subsequent periods of 
public spending cuts and ﬁ scal austerity.6 Thus, many 
aﬀ ected individuals who remain in work during these 
hard times encounter serious psychological stressors 
due to pernicious economic strains other than un-
employment, including falling income, ‘zero-hour’ 
contracting, job insecurity, bankruptcy, debt, and home 
repossession.7 Caution should therefore be exercised 
when considering estimated numbers of additional 
suicide cases attributable to global economic downturn, 
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frequency of use in prediction of risk of psychosis, and 
could have a substantial eﬀ ect on public health. 
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